Strategies shown to reduce systemic inflammatory markers in chronic kidney disease and/or chronic dialysis patients include pharmacological and non-pharmacological strategies. Pharmacological strategies that have been evaluated are specific anti-cytokine therapies, as well as non-specific agents with anti-inflammatory properties, including statins, angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB), cholecalciferol (vit D), sevelamer, peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists, and growth hormone. Non-pharmacological strategies that have been shown to lower systemic inflammatory markers include changes in dialysis delivery, dietary factors (catechins [green tea extract], omega-3 fatty acids, soy isoflavones, low fructose, and pomegranate juice), and exercise.